8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 8, 2019

CORE LABORATORIES N.V.

(Exact name of registrant as specified in its charter)

The Netherlands	001-14273	Not Applicable
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
Strawinskylaan 913 Tower A, Level 9 1077 XX Amsterdam The Netherlands		Not Applicable
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (31-20) 420-3191

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock (Par Value EUR 0.02)	CLB	New York Stock Exchange

Common Stock (Par Value EUR 0.02) CLB Euronext Amsterdam Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On October 8, 2019, Core Laboratories N.V. issued a press release announcing a quarterly cash dividend of $0.55 per share of common stock for shareholders of record on October 18, 2019 and payable November 19, 2019.

The full text of the press release is set forth in Exhibit 99.1 attached hereto.

The information in this Report and the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly stated by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1         Press release issued on October 8, 2019 *

* This exhibit is intended to be furnished and shall not be deemed "filed" for purposes of the Exchange Act.

CORE LABORATORIES N.V.

EXHIBIT INDEX TO FORM 8-K

EXHIBIT NO.	ITEM
99.1	Press release issued on October 8, 2019 *

* This exhibit is intended to be furnished and shall not be deemed "filed" for purposes of the Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Core Laboratories N.V.
Dated:  October 8, 2019	By	/s/ Christopher S. Hill
		Christopher S. Hill
		Chief Financial Officer

EX-99.1

 

FOR IMMEDIATE RELEASE

CORE LAB ANNOUNCES Q4 2019 QUARTERLY DIVIDEND

AMSTERDAM (8 October 2019) - The Board of Supervisory Directors of Core Laboratories N.V. (NYSE: "CLB US" andEuronextAmsterdamExchange:"CLBNA")hasannouncedacashdividendof$0.55pershareofcommonstock payable in the fourth quarter of 2019. This fourth quarter dividend will mean a total payout of $2.20 per share of common stock will have been made for the entire 2019 year. The quarterly $0.55 per share cash dividend will be payable on Tuesday, 19 November 2019, to shareholders of record on Friday, 18 October 2019. Dutch withholding tax will be deducted from the dividend at a rate of15%.

Any determination to declare a future quarterly cash dividend, as well as the amount of any such cash dividend that may be declared, will be based on the Company's financial position, earnings, earnings outlook, capital expenditure plans, ongoing share repurchases, potential acquisition opportunities, and other relevant factors at the time.

The Company has scheduled a conference call to discuss Core's third quarter 2019 earnings. The call will begin at 7:30 a.m. CDT / 2:30 p.m. CEST on Thursday, 24 October 2019. To listen to the call, please go to Core's website at www.corelab.com.

CoreLaboratoriesN.V.(www.corelab.com)isaleadingproviderofproprietaryandpatentedreservoirdescriptionand production enhancement services used to optimize petroleum reservoir performance. The Company has over 70 offices in more than 50 countries and is located in every major oil-producing province in theworld.

Thisreleaseincludesforward-lookingstatementsregardingthefuturerevenues,profitability,businessstrategiesand developments of the Company made in reliance upon the safe harbor provisions of Federal securities law. The Company's outlook is subject to various important cautionary factors, including risks and uncertainties related to the oil and natural gas industry, business conditions, international markets, international political climates and other factors as more fully described in the Company's 2018 Form 10-K filed on 11 February 2019, and in other securities filings. These important factors could cause the Company's actual results to differ materially from those described in theseforward-lookingstatements.SuchstatementsarebasedoncurrentexpectationsoftheCompany'sperformance and are subject to a variety of factors, some of which are not under the control of the Company. Because the information herein is based solely on data currently available, and because it is subject to change as a result of changes in conditions over which the Company has no control or influence, such forward-looking statements should not be viewed as assurance regarding the Company's future performance. The Company undertakes no obligation to publicly update any forward-looking statement to reflect events or circumstances that may arise after the date of this pressrelease.

For more information contact:

Gwen Y. Schreffler – Senior VP Corporate Development and Investor Relations, +1 713 328 6210

investor.relations@corelab.com

###

XML

Document And Entity Information	Oct. 08, 2019
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Oct. 08, 2019
Entity Registrant Name	CORE LABORATORIES N V
Entity Central Index Key	0001000229
Entity Emerging Growth Company	false
Entity File Number	001-14273
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Address, Address Line One	Strawinskylaan 913Tower A, Level 9
Entity Address, Address Line Two	1077 XX
Entity Address, City or Town	Amsterdam
Entity Address, Country	NL
City Area Code	31-20
Local Phone Number	420-3191
Entity Incorporation, State or Country Code	P7
Entity Address, Postal Zip Code	1077
Title of each class	Common Stock (Par Value EUR 0.02)
Trading Symbol	CLB
Name of each exchange on which registered	NYSE